An­a­lysts are quick to pan Eli Lil­ly's puz­zling first cut of pos­i­tive clin­i­cal da­ta for its Covid-19 an­ti­body

Eli Lil­ly spot­light­ed a suc­cess for one of 3 dos­es of their close­ly-watched Covid-19 an­ti­body drug Wednes­day morn­ing. But an­a­lysts quick­ly high­light­ed some ob­vi­ous anom­alies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER